Airways disease - A vast global challenge

More than one billion people are affected by respiratory disease globally

65million people have moderate to severe COPD with 3 million deaths attributed annually, making it the third leading cause of premature death worldwide

335 million people suffer from asthma, the most common chronic childhood disease affecting 14% of children globally

Lower respiratory tract infections cause an estimated 4 million deaths annually, a leading cause of death in children

Influenza infection alone is responsible for 250,000 to 500,000 deaths annually with healthcare costs estimated to be between $71 and $167 billion annually

These numbers continue to increase

Airways disease - A vast global challenge

More than one billion people are affected by respiratory disease globally

65million people have moderate to severe COPD with 3 million deaths attributed annually, making it the third leading cause of premature death worldwide

335 million people suffer from asthma, the most common chronic childhood disease affecting 14% of children globally

Lower respiratory tract infections cause an estimated 4 million deaths annually, a leading cause of death in children

Influenza infection alone is responsible for 250,000 to 500,000 deaths annually with healthcare costs estimated to be between $71 and $167 billion annually

These numbers continue to increase

A-IR is the next-generation respiratory focused clinical research organisation (CRO). We provide a bespoke solution to the assessment and development of new vaccine and therapeutic approaches for respiratory infection, disease and allergy.

Welcome to A-IR

Operating from a state of the art research laboratory in the UK and across a collaborative clinical network of sites across mainland Europe, the US and Asia, we leverage our unparalleled knowledge base, robust study management and broad spectrum biomarker capacity to execute transnational clinical studies and provide clients with the ability to accelerate their own asset development.

We pride ourselves on our considerable experience and detailed understanding of delivering excellence in the academic, government and commercial sectors of respiratory disease and our ability to provide an end-to-end solution.

A-IR Services

Conception

Creating robust, progressive study designs for investigation of novel prophylactics & therapeutics providing the optimum assessment setting

Approvals

Leading through the undulating regulatory landscape during the study set-up and inception

Support

Support provision: Site feasibility, study monitoring, Biostatisticians & Pharmacovigilance as required

Execution

Execution of the clinical study, exacting precision, integrity & communication throughout

Analysis

State-of-the-art immunology, virology & biomarker analysis, providing Important disease/treatment understanding along with valuable MOA insight intervention

Delivery

Data Insight & interpretation Dissemination through publication and investigatory-led symposia.
Assisting regulatory approvals process

A-IR Solution

A-IR Advantage

Innovative approaches to naturally occurring infection studies, alongside specialism in allergen challenge and live virus challenge models – we offer a unique opportunity to test efficacy of novel treatments and deliver a competitive advantage

Defined virus delivery

Delivery of a defined virus dose, at a defined time point to all subjects, alleviating variables associated with pathogen, seasonality, inflammation kinetics and antiviral immunity

GMP human inoculum

Use of GMP human virus inoculum, including reverse engineered clones, providing the unique ability to determine changes to the pathogen as a consequence of treatment inventions.

Understanding

In-depth understanding of the underlying immunopathology & infection cycle, delivering robust data on a broad range of clinically relevant endpoints

All this culminating to deliver the complete clinical study package

About A-IR

A-IR, your next generation CRO, launched to offer novel opportunities in respiratory indications including live virus challenge with Influenza, Rhinovirus and Respiratory Syncytial Virus, alongside naturally occurring infection studies both in healthy and chronic airways disease populations.

Founders Cathryn A. Macrae and Dr Ross P. Walton were also founding members of the first CRO to offer common cold challenge studies in patients with asthma and Chronic Obstructive Pulmonary Disease (COPD) where they pioneered, refined and expanded their expertise in investigative application of virus challenge for the benefit of clients in the commercial setting. They are now joined by David Kwasha in bringing the A-IR advantage to the market.

Cathryn A. Macrae

Co-Founder & Board Director (New York City, USA) a life sciences entrepreneur, has been operating at the inter-section of clinical science and private industry for over 25 years for government, private and public industry, as well as NGOs.
Cathryn has a market-leading ability to form strategic alliances and coalitions with leading sector players, as well as bringing together world-renowned opinion leaders from academia, government and industry. Cathryn has also applied her unique talent and experience throughout her career to identifying and enabling strategic funding pathways across a broad range of health care endeavours.

Ross P. Walton MSc. PhD.

Co-Founder & Board Director (London, UK) has a PhD from Imperial College specialising in respiratory viral infections and their interplay with inflammatory airways disease. A cellular immunologist by training, Ross has over 17 years of experience in developing viral challenge models and employing state-of-the-art analytical approaches in patient samples. In addition to his scientific expertise, academic network and knowledge base, Ross has unique strategic capabilities in business development, lifecycle management and leadership.

David Kwasha

Managing Director & Head of Asia Pacific Region (Sydney, Australia) has forged a unique and globally successful 30 year career in senior leadership in the pharmaceutical industry. His experience has traversed medical affairs, R&D, marketing, market access, business development, commercial operations and senior executive leadership at local, regional and global levels. Following a stellar 10 year career with Roche where David achieved renown performance as a Global Business and Lifecycle Management Leader, he spent the last 20 years as a pioneering leader for new rare disease companies such as Actelion and Alexion from start- up to global  operational success.

Insight and case specific research and clinical science expertise is enhanced by a committed network of true, key world opinion leaders in respiratory infection and disease.

Contact Us